Overview
Balance Sheet
Cash Flow
Growth Analysis
2023
2022
2021
2020
2019
Profitability Metrics
Gross Margin
71.64%
Operating Margin
33.93%
Net Margin
21.52%
Efficiency Metrics
Revenue per Expense Ratio
1.51
R&D as % of Revenue
0.00%
Earnings Quality
EBITDA Margin
60.12%
Income Tax Rate
1.70%
EPS
3.4600000000
Balance Sheet Analysis
Current Ratio
0.40
Cash Ratio
0.04
Working Capital
$-1.55B
Debt to Equity
4.52
Debt to Assets
74.79%
Equity Ratio
16.56%
Cash Flow Analysis
Operating Cash Flow Ratio
44.78%
Free Cash Flow Ratio
24.38%
CapEx to Revenue
20.40%
Dividends Paid
$2.72B
Stock Buybacks
$30.00M
Total Shareholder Returns
$2.75B
Cash Position Change
-14.29%
Key Takeaways (2023 FY)
Revenue declined by 0.071571714858288%, indicating potential market challenges
Increased dividend payments by 4.41%
Detailed Growth Metrics
Core Performance
Revenue
-0.07%
Net Income
-10.33%
EPS
-10.59%
Operating Income
-3.74%
Operational Efficiency
R&D Expenses
-100.00%
SG&A Expenses
1.20%
Operating Cash Flow
8.62%
Free Cash Flow
8.55%
Balance Sheet Health
Assets
-1.01%
Debt
3.05%
Book Value per Share
-14.53%
Inventory
0.00%
Shareholder Returns
Dividends per Share
4.41%
Shares Outstanding
0.23%
Long Term Trends
3Y Revenue/Share
16.51%
5Y Revenue/Share
22.50%
3Y Dividend/Share
21.19%
5Y Dividend/Share
36.74%